Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects

被引:36
作者
Frye, RF
Branch, RA
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15261 USA
关键词
acetylation; caffeine; chlorzoxazone; cytochrome P450; dapsone; deacetylation; debrisoquine; disulfiram; mephenytoin;
D O I
10.1046/j.1365-2125.2002.01522.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Short-term disulfiram administration has been shown to selectively inhibit CYP2E1 activity but the effects of chronic disulfiram administration on the activities of drug metabolizing enzymes is unclear. The purpose of this study was to evaluate the effects of disulfiram given for 11 days on selected drug metabolizing enzyme activities. Methods Seven healthy volunteers were given disulfiram 250 mg daily for 11 days. Activities of the drug metabolizing enzymes CYP1A2, CYP2C19, CYP2D6, CYP2E1 and N-acetyltransferase were determined using the probe drugs caffeine, mephenytoin, debrisoquine, chlorzoxazone, and dapsone, respectively. Chlorzoxazone was administered before disulfiram administration and after the second and eleventh doses of disulfiram, while the other probe drug, were given before disulfiram administration and after the eleventh disulfiram dose. Results Disulfiram administration markedly inhibited chlorzoxazone 6-hydroxylation by more than 95%, but did not affect metabolism of debrisoquine or mephenytoin. Caffeine N3-demethylation was decreased by 34% (P<0.05). Monoacetyldapsone concentrations were markedly elevated by disulfiram administration resulting in a nearly 16-fold increase in the dapsone acetylation index, calculated as the plasma concentration ratio of monoacetyldapsone to dapsone. CYP-mediated dapsone N-hydroxylation was not significantly altered. Conclusions These data suggest that disulfiram-mediated inhibition is predominantly selective for CYP2E1. The magnitude of CYP2E1 inhibition was similar after both acute and chronic disulfiram administration. The effects on caffeine N3-demethylation (CYP1A2) and dapsone metabolism suggest that chronic disulfiram administration may affect multiple drug metabolizing enzymes, which could potentially complicate the use of chronically administered disulfiram as a diagnostic inhibitor of CYP2E1.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 41 条
[1]   INHIBITION OF ELIMINATION OF CAFFEINE BY DISULFIRAM IN NORMAL SUBJECTS AND RECOVERING ALCOHOLICS [J].
BEACH, CA ;
MAYS, DC ;
GUILER, RC ;
JACOBER, CH ;
GERBER, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (03) :265-270
[2]  
BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
[3]   INTERACTION BETWEEN 2 PROBES USED FOR PHENOTYPING CYTOCHROMES P4501A2 (CAFFEINE) AND P4502E1 (CHLORZOXAZONE) IN HUMANS [J].
BERTHOU, F ;
GOASDUFF, T ;
LUCAS, D ;
DREANO, Y ;
LEBOT, MH ;
MENEZ, JF .
PHARMACOGENETICS, 1995, 5 (02) :72-79
[4]   Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine [J].
Damkier, P ;
Hansen, LL ;
Brosen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (06) :829-838
[5]  
DIQUET B, 1990, EUR J CLIN PHARMACOL, V38, P157
[6]  
Emery MG, 1999, J PHARMACOL EXP THER, V291, P213
[7]   Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography [J].
Frye, RF ;
Stiff, DD .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (02) :291-296
[8]   Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection [J].
Frye, RF ;
Branch, RA .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 677 (01) :178-182
[9]   Validation of the five-drug ''Pittsburgh cocktail'' approach for assessment of selective regulation of drug-metabolizing enzymes [J].
Frye, RF ;
Matzke, GR ;
Adedoyin, A ;
Porter, JA ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :365-376
[10]  
Frye RF, 1999, J CLIN PHARMACOL, V39, P1177